Abatacept
- Generic Name
- Abatacept
- Brand Names
- Orencia
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 332348-12-6
- Unique Ingredient Identifier
- 7D0YB67S97
- Background
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of tw...
- Indication
Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and for the treatment of active psoriatic arthritis. In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.
...
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Moderate to Severe Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Psoriatic Arthritis
- Associated Therapies
- -
Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
- First Posted Date
- 2007-05-02
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 20
- Registration Number
- NCT00468208
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Boston University School of Medicine, Boston, Massachusetts, United States
🇺🇸Mayo Clinic College of Medicine, Rochester, Minnesota, United States
A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
- Conditions
- Interventions
- First Posted Date
- 2007-03-02
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 10
- Registration Number
- NCT00442611
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
- Conditions
- Interventions
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2015-03-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 423
- Registration Number
- NCT00430677
- Locations
- 🇺🇸
Wallace Rheumatic Study Center, Los Angeles, California, United States
🇺🇸Northshore Lij Health System, Lake Success, New York, United States
🇺🇸Ok Medical Research Foundation, Oklahoma City, Oklahoma, United States
A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 50
- Registration Number
- NCT00420199
- Locations
- 🇬🇧
Local Institution, Leeds, North Yorkshire, United Kingdom
A Study of Abatacept in Patients With Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 591
- Registration Number
- NCT00410410
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Atlanta Gastroenterology Associates, Atlanta, Georgia, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2013-08-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 113
- Registration Number
- NCT00409838
- Locations
- 🇰🇷
Local Institution, Seoul, Korea, Republic of
A Study of Abatacept in Patients With Active Crohn's Disease
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 451
- Registration Number
- NCT00406653
- Locations
- 🇺🇸
Allegheny Center For Digestive Health, Pittsburgh, Pennsylvania, United States
🇺🇸Consultants For Clinical Research, Cincinnati, Ohio, United States
🇺🇸Nashville Medical Research, Nashville, Tennessee, United States
A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate
- First Posted Date
- 2006-06-28
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 194
- Registration Number
- NCT00345748
- Locations
- 🇯🇵
Local Institution, Tochigi, Japan
Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
- Conditions
- First Posted Date
- 2006-03-27
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 45
- Registration Number
- NCT00306878
- Locations
- 🇺🇸
Local Institution, Pittsburgh, Pennsylvania, United States
Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2006-01-20
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 210
- Registration Number
- NCT00279760
- Locations
- 🇬🇧
Local Institution, Leeds, United Kingdom
🇧🇪Local Instiution, Bruxelles, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.